Spotlight
- French Biotech: In Pursuit of Funding
-
With government funding in limited supply, biotech companies in France have developed strategies to build financial muscle and ensure their economic vision for the future.
- India's Road to Success
-
India is establishing itself as a global leader for pharmaceutical research, and increasingly, commercialization.
- HIV/AIDS in South Africa: Progress Through Collaboration
-
As South Africa grapples with the world’s largest population suffering with HIV/AIDS, pharmaceutical manufacturers and non-government organizations are working together to fight the pandemic and search for a cure.
Development
- Control Mechanism
-
A rapidly increasing rate of type 2 diabetes has researchers scrambling for new interventions to combat the chronic condition.
- Image Awareness
-
Radiological biomarkers hold the potential to be a positive force in pharmaceutical research, but the adoption of imaging techniques as a useful tool for drug development has been slow to materialize.
- Streamlining Safety Data
-
With electronic data collection becoming more mainstream, clinical trialists are now looking to incorporate safety data into the electronic mix as well.
Management
- Rethinking Informed Consent
-
Cultural understanding, technology and pragmatism are helping create new approaches to clinical research subject enrollment.
- Change is Constant
-
To fully optimize adaptive clinical trial design, the proper technological tools must be in place.
- The Calm Before the Storm
-
A number of fundamental factors could lead to a new and accelerated wave of consolidation in the pharmaceutical and biotech industries.
Commercialization
- Same Difference
-
Across Europe, incentive programs have been designed, redesigned and implemented to encourage physicians to prescribe generic medications. Although the practice may help reduce costs, does it represent value for everyone?
- Knocking on a Difficult Door
-
Selling to managed care organizations requires an entirely different approach than traditional pharmaceutical detailing.
- Access to Innovation
-
Ideally, pharmaceutical pricing provides an incentive for innovation and also makes quality medicines accessible to all. Achieving this delicate balance, however, is proving to be a difficult proposition.
Web Exclusives
- Turning the Corner
-
After decades of neglect, leading to a rapid increase in incidence, tuberculosis started gaining attention from industrialized nations over the past 10 years. With this new focus, TB’s incidence has started to decrease—but barely.
- A Weighty Problem
-
As pharmaceutical companies search for a blockbuster fat-fighting drug, the biggest battle is against side effects.
- Ahead of the Curve
-
As a follow-on biologics pathway inches closer to reality, interested companies must consider biologics’ unique characteristics when preparing to enter the game.
Columns
- Safety through Standards
-
Paula Brown Stafford, executive vice president of global data management at Quintiles, discusses how universal data standards can help ensure better patient safety across all phases of clinical research.
- Anatomy of a Managed Partnership
-
Michel Abiteboul, vice president of global business development at NovaQuest, outlines various partnering solutions for today’s global pharmaceutical marketplace.
- A New Gold Standard for Pricing
-
Dr. John Doyle, practice leader for market access at Quintiles Consulting, introduces the concept of a health economic balance sheet and evidence-based pricing for biopharmaceutical valuation.
- >> more Columns
Special Report - June 2008
- BIOspeak
-
Jim Greenwood, president and CEO of the Biotechnology Industry Organization (BIO) and a former member of the U.S. Congress, discusses the most critical policy challenges facing the industry today.
- Which Way Forward?
-
Amidst the constant need to secure steady financing, emerging biotech companies are considering options that will not only produce a larger return, but also increase the likelihood of getting a product to market.
- The New Face of Outsourcing
-
The pressing need to control costs and reduce development timelines has led many biopharmaceutical manufacturers to increasingly outsource components of their clinical research programs.
- >> more
Web Exclusives
- Turning the Corner
-
After decades of neglect, leading to a rapid increase in incidence, tuberculosis started gaining attention from industrialized nations over the past 10 years. With this new focus, TB’s incidence has started to decrease—but barely.
- A Weighty Problem
-
As pharmaceutical companies search for a blockbuster fat-fighting drug, the biggest battle is against side effects.